On December 18, 2006, when the second front page news report about Eli Lilly's concealed documents ran in The New York Times, "Zyprexa Sales Rep" was posted on YouTube by a group of physicians, PharmedOut.

There are currently about 100,000 pharmaceutical sales reps according to Pharma Marketing Blog.

For insight into what sales reps talk about among thermselves, see:

http://pharmamkting.blogspot.com/2007/01/are-sales-reps-necessary.html

Instead of coming clean, Lilly is currently engaging in intimidation of legitimate critics and victims of its drug's hazardous effects.

Lilly's effort is to prevent the public from learning the truth about the hazards of Zyprexa–as documented in the company's own internal documents.

The content of those documents were outlined on the front page of The New York Times, Dec. 17, 18:

https://ahrp.org/cms/content/view/412/29/ and https://ahrp.org/cms/content/view/414/29/

Lilly attorneys obtained court ordered temporary injunctions preventing the documents from reaching law enforcement officials who may be prompted to prosecute the company for criminal concealment of evidence and for off-label marketing to primary care physicians of a drug approved for schizophrenia and bipolar condition–a drug whose disruption of normal metabolic function and triggering catastrophic health hazards including cardiovascular abnormalities. All of which are shortening the life expectancy of those who take if for any length of time.